NCT04118192 (NOSTRA) is a clinical trial of Tumour bed core biopsy in Breast Cancer, sponsored by University of Birmingham.

Who is sponsoring NCT04118192?

NCT04118192 is sponsored by University of Birmingham.

What drugs are being tested in NCT04118192?

Interventions in NCT04118192: Tumour bed core biopsy.

What condition does NCT04118192 study?

NCT04118192 studies Breast Cancer.

Is NCT04118192 still recruiting?

NCT04118192 is currently active, enrolled. Last updated 24 January 2025.

Last reviewed 2025-01-24 · How we verify

NCT04118192: NOSTRA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NOSTRA-Feasibility Study: A Study Looking at Ultrasound Guided Biopsies for Breast Cancer

Active, enrolled Last updated 24 January 2025

What this trial tests

trial testing Tumour bed core biopsy in Breast Cancer in 72 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

22 May 2019

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	University of Birmingham
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	72
Start date	22 May 2019
Primary completion	31 December 2025
Estimated completion	31 December 2025
Sites	24 locations across United Kingdom

Drugs / interventions tested

Tumour bed core biopsy

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

University of Birmingham

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective non-randomised multi-centre feasibility study to assess if patients with residual cancer following dual-targeted neoadjuvant chemotherapy treatment for HER2-positive, ER-negative early breast cancer can be identified by multiple ultrasound (US)-guided tumour bed core biopsies

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Identifying research priorities in breast cancer surgery: a UK priority setting partnership with the James Lind Alliance.
Potter S, Fairhurst K, Cowan K, Vincent S, et al · · 2023 · cited 18× · PMID 36319906 · DOI 10.1007/s10549-022-06756-4
Locoregional Treatment for Early-Stage Breast Cancer: Current Status and Future Perspectives.
Lavasani S, Healy E, Kansal K. · · 2023 · cited 3× · PMID 37623026 · DOI 10.3390/curroncol30080545
The Role of Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapies in Early-Stage Breast Cancer: Current Practices, Treatment De-escalation, and Future Prospects.
Hashem M, Rehman S, Salhab M. · · 2024 · cited 1× · PMID 38558735 · DOI 10.7759/cureus.55230

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other University of Birmingham trials

Trials by the same sponsor.

NCT07160686 — Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment · Phase 3 · not yet recruiting
NCT07446166 — TETANUS Antibody Detection in Saliva Study · NA · not yet recruiting
NCT07294794 — Personalised Pharmacometabolomic-guided Strategy Trial to Optimise Treatment for Hypertension · NA · not yet recruiting
NCT07246356 — Feasibility and Efficacy of GTEP for Birth Trauma · NA · recruiting
NCT06932653 — Reducing Deaths After Surgery in Low- and Middle-income Countries: A Pilot Cluster Randomised Trial · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04118192 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Birmingham
Last refreshed: 24 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04118192.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing